Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
95.1M
-
Shares change
-
+8.85M
-
Total reported value, excl. options
-
$1.08B
-
Value change
-
+$107M
-
Put/Call ratio
-
0.17
-
Number of buys
-
71
-
Number of sells
-
-72
-
Price
-
$11.40
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q2 2022
186 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q2 2022.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95.1M shares
of 226M outstanding shares and own 42.04% of the company stock.
Largest 10 shareholders include TPG GP A, LLC (18.7M shares), VANGUARD GROUP INC (8.41M shares), BlackRock Inc. (8.01M shares), Woodline Partners LP (5.86M shares), STATE STREET CORP (5.65M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.56M shares), PRIMECAP MANAGEMENT CO/CA/ (4.88M shares), EcoR1 Capital, LLC (4.49M shares), Capital International Investors (4.33M shares), and Wildcat Capital Management, LLC (2.13M shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.